These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 15900797

  • 1. Combining traditional agents and biologics for the treatment of psoriasis.
    Cather JC, Menter A.
    Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
    [Abstract] [Full Text] [Related]

  • 2. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 Mar; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 3. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
    Leon A, Nguyen A, Letsinger J, Koo J.
    Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017
    [Abstract] [Full Text] [Related]

  • 4. Biologic agents in the treatment of psoriasis.
    Guarneri F, Guarneri C, Guarneri B.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
    [Abstract] [Full Text] [Related]

  • 5. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH, Prinz J, Gottlieb AB.
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [Abstract] [Full Text] [Related]

  • 6. [Biologics in the treatment of psoriasis].
    Dissemond J, Grabbe S.
    MMW Fortschr Med; 2006 Sep 21; 148(38):42-4. PubMed ID: 17036963
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
    Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM.
    J Am Acad Dermatol; 2014 Dec 21; 71(6):1167-75. PubMed ID: 25260564
    [Abstract] [Full Text] [Related]

  • 8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct 21; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.
    Br J Dermatol; 2009 Jun 21; 160(6):1264-72. PubMed ID: 19120346
    [Abstract] [Full Text] [Related]

  • 10. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov 21; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 11. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK.
    J Cutan Med Surg; 2012 Nov 21; 16(3):153-68. PubMed ID: 22713438
    [Abstract] [Full Text] [Related]

  • 12. A new era in the management of psoriasis? The biologics: facts and controversies.
    Ferrándiz C, Carrascosa JM, Boada A.
    Clin Dermatol; 2010 Nov 21; 28(1):81-7. PubMed ID: 20082956
    [Abstract] [Full Text] [Related]

  • 13. Combining the new biologic agents with our current psoriasis armamentarium.
    Lebwohl M.
    J Am Acad Dermatol; 2003 Aug 21; 49(2 Suppl):S118-24. PubMed ID: 12894135
    [Abstract] [Full Text] [Related]

  • 14. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr 21; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 15. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Apr 21; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 16. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007 Apr 21; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 17. Biological agents in the treatment of psoriasis.
    Tzu J, Krulig E, Cardenas V, Kerdel FA.
    G Ital Dermatol Venereol; 2008 Oct 21; 143(5):315-27. PubMed ID: 18833073
    [Abstract] [Full Text] [Related]

  • 18. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI, Cohen AD, Wolf P, Gkalpakiotis S, Cazzaniga S, Stern RS, Hutten BA, Feldhamer I, Quehenberger F, Lichem R, Kojanova M, Adenubiova E, Addis A, Naldi L, Spuls PI.
    J Eur Acad Dermatol Venereol; 2018 Feb 21; 32(2):245-253. PubMed ID: 28898541
    [Abstract] [Full Text] [Related]

  • 19. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R, Tutrone WD, Weinberg JM.
    Curr Pharm Des; 2005 Feb 21; 11(2):273-80. PubMed ID: 15638763
    [Abstract] [Full Text] [Related]

  • 20. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
    JAMA Dermatol; 2015 Apr 21; 151(4):432-8. PubMed ID: 25517130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.